News
Welcome to the news and media section of our website, where we feature corporate news releases and media coverage of interest.
Show by Tag
NovaVive Inc. has signed a marketing services agreement with AABEX Animal Health for the U.S.A. AABEX is a new animal health sales and marketing company founded by Mark Hill, a seasoned industry professional from Merial Ltd.
Dr. Jeannette Kelly, veterinary oncologist with Veterinary Cancer Care, presented data from a study of multiple IV administrations of Immunocidin® in dogs and cats with various malignancies at the ACVIM Forum last week.
Amplimune®, our immunotherapeutic for calf scours, has received an Organic Materials Review Institute (OMRI) Listing in the U.S.A. This means that Amplimune can be used in compliance with the USDA National Organic Program.
NovaVive's Immunocidin® Equine anticancer immunotherapeutic for horses will be evaluated in a clinical study at Iowa State University (ISU) College of Veterinary Medicine in sarcoids and squamous cell carcinoma.
NovaVive's immunotherapeutic for the treatment of equine endometritis, Settle®, has been approved for sale to New Zealand veterinarians by the NZ regulator. It was previously approved for sale in the U.S. and Australia.
NovaVive's MCWF technology has demonstrated potential to control chronic Mycoplasma bovis (M. bovis) infection in dairy cows. M. bovis causes respiratory disease, ear infection, arthritis, mastitis, abortion and other issues.